DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (4305)

Hepatitis C Virus | Definition & Forecast | Overview

The hepatitis C virus (HCV) therapy market has been marked by tremendous growth and has undergone a rapid evolution of the treatment landscape with the launch of novel direct-acting antivirals (DAAs) and DAA combinations, including simeprevir (Janssen’s Olysio, Medivir’s Sovriad), sofosbuvir (Gilead’s Sovaldi), sofosbuvir/ledipasvir (Gilead’s Harvoni), ombitasvir/paritaprevir/ritonavir plus dasabuvir (AbbVie’s Viekira Pak), daclatasvir (Bristol-Myers Squibb’s Daklinza), Zepatier (Merck’s elbasvir/grazoprevir), and Epculsa (Gilead’s sofosbuvir/velpatasvir). The forthcoming rise of pangenetic regimens (, Epculsa, AbbVie’s glecaprevir/pibrentasvir, and Gilead’s sofobuvir)/velpatasvir/voxilaprevir) with potentially shorter treatment durations will not only expand treatment options for HCV patients, including difficult-to-treat patients (, DAA treatment failures), but is slated to shift the treatment paradigm once again triggering a departure in genotype-specific prescribing, which has traditionally been cornerstone of treatment for HCV. In this post-DAA era, commercial opportunity in the HCV market will continue to be driven by a large prevalent viremic population and relaxation of access restrictions that limited the uptake of highly efficacious, but costly DAA-based treatment options in cost-sensitive markets. However, as increased competition continues reduce the cost of treatment, the overall value of the market will gradually decline. Questions Answered: How large is the treatable Hepatitis C Virus (HCV) population and how will diagnosis/drug-treatment rates change over time? What is the current state of treatment for chronic HCV infection? Which are the most important drugs and why? What are interviewed experts’ insights on current treatment options? What clinical needs remain untapped? What pipeline products are most promising, and what sales/uptake could they secure in HCV markets? What therapies of note are progressing in earlier phases? What are the drivers and constraints in the HCV market, and how will the market evolve over the forecast period? Scope: Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan. Primary research: 22 country-specific interviews with thought leaders in HCV treatment. Epidemiology: Seroprevalence of HCV, prevalence of HCV viremia, and incidence of HCV viremia. Population segments in market forecast: Treatment-naive genotypes 1, 4, 5, and 6; treatment-naive genotype 2; treatment-naive genotype 3; treatment-experienced genotypes 1, 4, 5, and 6; treatment-experienced genotype 2; treatment-experienced genotype 3. Emerging therapies and current IFN-free therapies: Phase II: 5 drugs; Phase III: 1 drugs; preregistration: 1 drugs; registered: 9 drugs.